

Enroll in Interconnect[®]

Enrollment Form Checklist

In this packet, you will find all of the necessary forms to enroll your patients in Interconnect and give them access to a full suite of support services for OCALIVA[®] (obeticholic acid).^a

Please complete these forms and submit them to Interconnect:

By mail:

Interconnect
P.O. Box 580
Somerville, NJ 08876

By fax:

1-855-686-8730

By email:

info@interconnectsupport.com

Enrollment Form (Statement of Medical Necessity)

Patient Authorization Form

Copies of both sides of patient's pharmacy benefit card(s)

Copies of both sides of patient's insurance card(s)

Patient Assistance Application (if needed)

^aNot all patients will qualify for every service offering.

Please see Important Safety Information for OCALIVA on page 4 and [Full Prescribing Information, including Boxed WARNING](#) for OCALIVA or visit ocalivahcp.com. Rx only.

Interconnect[®]
SUPPORT SERVICES

A. Prescriber information

First name _____ Last name _____
Address _____
City _____ State _____ ZIP _____
Phone _____ Ext. _____ Fax _____
Primary contact email _____
Primary contact name _____ Clinic/facility name office _____
NPI no. _____ State license no. _____ Prescriber tax ID _____
Preferred contact: Email _____ Phone _____ Fax _____

B. Patient information

Male _____ Female _____ Date of birth _____ / _____ / _____
First name _____ Last name _____
Address _____
City _____ State _____ ZIP _____
Email _____ Phone _____
Preferred contact: Email _____ Phone _____ OK to leave message _____
Preferred language: English _____ Spanish _____ Other _____

Prescription drug information

Attach copies of both sides of patient's pharmacy benefit card(s).

Check if no coverage (If there is no coverage, please complete the Patient Assistance Application form)

Prescription insurance information

Attach copies of both sides of patient's insurance card(s).

Check if no coverage _____ Check if patient has secondary insurance _____

Primary insurance name _____ Policy no. _____
Group no. _____ Insurance company phone _____
Policy holder name _____ Last 4 digits of SSN _____

C. Prescription and medical information

Prescription for OCALIVA® (obeticholic acid): # of refills

5 mg, PO once daily x 30 days, #30 tablets _____
10 mg, PO once daily x 30 days, #30 tablets _____
Child-Pugh B/C: 5 mg, PO 1x/wk, #4 tablets _____
Child-Pugh B/C: 5 mg, PO 2x/wk, at least 3 days apart, #8 tablets _____
Child-Pugh B/C: 10 mg, PO 2x/wk, at least 3 days apart, #8 tablets _____

Prior authorization number (if known) _____
Prior authorization effective dates _____

Additional considerations: _____

Allergies: _____

Concurrent medications: _____

(Please note that Interconnect's limited specialty pharmacy network includes Accredo®, AllianceRx Walgreens Prime, and CVS Specialty™.)

C. Prescription and medical information (cont.)

Prescriber authorization

I authorize Intercept Pharmaceuticals, Inc. as my designated agent and on behalf of my patient to (1) forward this statement of medical necessity to furnish any information on this form to and recruit necessary patient information from the insurer of above-named patient and (2) forward this prescription, by fax or other mode of delivery, to the pharmacy. I certify that the rationale for prescribing OCALIVA is for a primary diagnosis of ICD-10: K74.3, and I will be supervising the patient's treatment accordingly.

Please select 1 option and sign only once below.

➔ Prescriber's signature (no stamps; substitution permitted) OR Prescriber's signature (dispense as written)
Date _____ Date _____

Intercept makes no representation that the information will comply with the requirements of any particular payer/insurer. The use of this information does not guarantee payment or that any payment received will cover your costs.

Special note: The physician is to comply with their state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance of state-specific requirements could result in outreach to the prescriber.

Statement of Medical Necessity

Primary diagnosis: ICD-10: K74.3

- When was the patient first diagnosed with PBC (month/year)? _____ / _____
- Antimitochondrial antibody test (AMA): Positive _____ Negative _____
- Patient biopsy: Positive _____ Negative _____ Not applicable _____
- Patient's current alkaline phosphatase (ALP) level: _____ units/L
- Patient's total bilirubin level: _____ mg/dL; Lab reference range: _____
- Is patient cirrhotic? Yes _____ No _____
If yes, Compensated _____ Decompensated (eg, ascites, variceal bleed, encephalopathy, jaundice) _____
- Child-Pugh score: A (5-6) _____ B (7-9) _____ C (10-15) _____ Unknown _____

Interim Access Program (IAP) Rx for OCALIVA

Optional, at no cost; patient must be commercially insured, a US resident, and have a pre-defined access barrier greater than 15 days. IAP requests will be reviewed by Interconnect® on a case by case basis. Patient authorization signatures on the second page of the Patient Consent Information form are needed to enroll in the IAP.

I authorize the use of IAP where applicable

Please sign and fax the completed form and required documentation to 1-855-686-8730

The form may also be sent by
Mail: Interconnect, P.O. Box 580, Somerville, NJ 08876
Email: info@interconnectsupport.com
Additional documentation attached

For Office Use Only

Interconnect Patient ID # _____

Please see Important Safety Information for OCALIVA on page 4 and [Full Prescribing Information, including Boxed WARNING](#) for OCALIVA or visit [ocalivahcp.com](#). Rx only.

PAGE 2

Starting Dosage

The recommended starting dosage of OCALIVA is 5 mg orally once daily in adults who have not achieved an adequate response to an appropriate dosage of UDCA for at least 1 year or are intolerant to UDCA.

Dosage Titration

If an adequate reduction in ALP and/or total bilirubin has not been achieved after 3 months of OCALIVA 5 mg once daily, and the patient is tolerating OCALIVA, increase the dosage of OCALIVA to 10 mg once daily to improve response. Initiation of therapy with a starting dosage of OCALIVA 10 mg once daily is not recommended due to an increased risk of pruritus.

Maximum Dosage

The maximum recommended dosage of OCALIVA is 10 mg once daily.

Dosage Adjustment in Hepatic Impairment

Treatment with OCALIVA in patients with moderate and severe hepatic impairment should be initiated and monitored by a healthcare provider with experience managing PBC. The recommended starting dosage of OCALIVA for moderate (Child-Pugh Class B) and severe (Child-Pugh Class C) hepatic impairment is 5 mg once weekly.

If an adequate reduction in ALP and/or total bilirubin has not been achieved after 3 months of OCALIVA 5 mg once weekly, and the patient is tolerating the drug, increase the dosage of OCALIVA to 5 mg twice weekly (at least three days apart) and subsequently to 10 mg twice weekly (at least three days apart) depending on response and tolerability.

Monitor patients during treatment with OCALIVA for the occurrence of liver-related adverse reactions. Weigh the potential risks against the benefits of continuing treatment with OCALIVA in patients who have experienced clinically significant liver-related adverse reactions.

For complete prescribing information please refer to the OCALIVA Package Insert.

The Child-Pugh Score¹

Factor	1 point	2 points	3 points
Bilirubin (mg/dL)	<2	2-3	>3
Albumin (g/dL)	>3.5	2.8-3.5	<2.8
Ascites	None	Slight	Moderate
Encephalopathy Grade	None	1 or 2	3 or 4
International Normalized Ratio (INR)	<1.7	1.7 to 2.3	>2.3

	Class A	Class B	Class C
Total points	5-6	7-9	10-15

1. OCALIVA [package insert]. New York, NY: Intercept Pharmaceuticals, Inc.; 2020.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

OCALIVA is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.

This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

WARNING: HEPATIC DECOMPENSATION AND FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR C OR DECOMPENSATED CIRRHOSIS

- In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with Primary Biliary Cholangitis (PBC) with decompensated cirrhosis or Child-Pugh Class B or C hepatic impairment when OCALIVA was dosed more frequently than recommended.
- The recommended starting dosage of OCALIVA is 5 mg once weekly for patients with Child-Pugh Class B or C hepatic impairment or a prior decompensation event.

Contraindications

OCALIVA is contraindicated in patients with complete biliary obstruction.

Warnings and Precautions

Hepatic Decompensation and Failure in Incorrectly-Dosed PBC Patients with Child-Pugh Class B or C or Decompensated Cirrhosis

In postmarketing reports, hepatic decompensation and failure, in some cases fatal, have been reported in patients with decompensated cirrhosis or Child-Pugh B or C hepatic impairment when OCALIVA was dosed more frequently than the recommended starting dosage of 5 mg once weekly. Reported cases typically occurred within 2 to 5 weeks after starting OCALIVA and were characterized by an acute increase in total bilirubin and/or ALP concentrations in association with clinical signs and symptoms of hepatic decompensation (e.g., ascites, jaundice, gastrointestinal bleeding, worsening of hepatic encephalopathy). Patients who died due to liver-related complications generally had decompensated cirrhosis prior to treatment and were started on OCALIVA 5 mg once daily, which is 7-fold greater than the once-weekly starting regimen in this population.

Routinely monitor patients for progression of PBC disease, including liver-related complications, with laboratory and clinical assessments. Dosage adjustment, interruption or discontinuation may be required. Close monitoring is recommended for patients at an increased risk of hepatic decompensation. Severe intercurrent illnesses that may worsen renal function or cause dehydration (e.g., gastroenteritis), may exacerbate the risk of hepatic decompensation. Interrupt treatment with OCALIVA in patients with laboratory or clinical evidence of worsening liver function indicating risk of decompensation, and monitor the patient's liver function. Consider discontinuing OCALIVA in patients who have experienced clinically significant liver-related adverse reactions. Discontinue OCALIVA in patients who develop complete biliary obstruction.

Liver-Related Adverse Reactions

Dose-related, liver-related adverse reactions including jaundice, worsening ascites and primary biliary cholangitis flare have been observed in clinical trials, as early as one month after starting treatment with OCALIVA 10 mg once daily up to 50 mg once daily (up to 5-times the highest recommended dosage). Monitor patients during treatment with OCALIVA for elevations in liver biochemical tests and for the development of liver-related adverse reactions.

Severe Pruritus

Severe pruritus was reported in 23% of patients in the OCALIVA 10 mg arm, 19% of patients in the OCALIVA titration arm, and 7% of patients in the placebo arm in a 12-month double-blind randomized controlled trial of 216 patients. Severe pruritus was defined as intense or widespread itching, interfering with activities of daily living, or causing severe sleep disturbance, or intolerable discomfort, and typically requiring medical interventions. Consider clinical evaluation of patients with new onset or worsening severe pruritus. Management strategies include the addition of bile acid resins or antihistamines, OCALIVA dosage reduction, and/or temporary interruption of OCALIVA dosing.

Reduction in HDL-C

Patients with PBC generally exhibit hyperlipidemia characterized by a significant elevation in total cholesterol primarily due to increased levels of high-density lipoprotein-cholesterol (HDL-C). Dose-dependent reductions from baseline in mean HDL-C levels were observed at 2 weeks in OCALIVA-treated patients, 20% and 9% in the 10 mg and titration arms, respectively, compared to 2% in the placebo arm. Monitor patients for changes in serum lipid levels during treatment. For patients who do not respond to OCALIVA after 1 year at the highest recommended dosage that can be tolerated (maximum of 10 mg once daily), and who experience a reduction in HDL-C, weigh the potential risks against the benefits of continuing treatment.

Adverse Reactions

The most common adverse reactions occurring in $\geq 5\%$ of subjects taking OCALIVA were pruritus, fatigue, abdominal pain and discomfort, rash, oropharyngeal pain, dizziness, constipation, arthralgia, thyroid function abnormality, and eczema.

Drug Interactions

• Bile Acid Binding Resins

Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the absorption, systemic exposure, and efficacy of OCALIVA. If taking a bile acid binding resin, take OCALIVA at least 4 hours before or 4 hours after taking the bile acid binding resin, or at as great an interval as possible.

• Warfarin

The International Normalized Ratio (INR) decreased following coadministration of warfarin and OCALIVA. Monitor INR and adjust the dose of warfarin, as needed, to maintain the target INR range when coadministering OCALIVA and warfarin.

• CYP1A2 Substrates with Narrow Therapeutic Index

Obeticholic acid, the active ingredient in OCALIVA, may increase the exposure to concomitant drugs that are CYP1A2 substrates. Therapeutic monitoring of CYP1A2 substrates with a narrow therapeutic index (e.g. theophylline and tizanidine) is recommended when coadministered with OCALIVA.

• Inhibitors of Bile Salt Efflux Pump

Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts including taurine conjugate of obeticholic acid in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitor serum transaminases and bilirubin.

Please see [Full Prescribing Information, including Boxed WARNING](#) for OCALIVA or visit ocalivahcp.com.

To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844- 782-ICPT or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PAGE 4

Interconnect
SUPPORT SERVICES

Patient name

Date of birth

Patient email

Phone number

I. Patient Authorization to Share Personal Health Information

The Interconnect® Support Services program provides services which vary from patient to patient, such as prescription management, support in securing reimbursement, referrals to patient financial support programs, drug shipment and refills outreach, compliance and persistency messaging to patients and the patients' physicians, no-cost medication to qualified patients, and other related services in connection with Intercept products and programs (the "Program"). The Program services may change from time to time.

This Authorization will allow the patient's healthcare provider(s) and health insurer(s) to share information with Intercept Pharmaceuticals, Inc. and its affiliates and their employees, including field representatives (collectively, "Intercept"), as well as third-party companies working on Intercept's behalf, for the purposes described in this Authorization.

AUTHORIZATION: By signing this Authorization, I (the patient or the patient's personal representative) authorize each of my physicians, pharmacists, and other healthcare providers (collectively, "Healthcare Providers") and each of my health insurers (collectively, "Insurers") to use and/or disclose the personal health information described below to Intercept and third parties administering Program services (including any Intercept service providers), for the purposes described in this Authorization. My personal health information may be disclosed orally or in writing, including by facsimile, email and/or through other data transfer means.

My Healthcare Providers and Insurers may disclose to Intercept and other third parties helping to administer Program services (including any Intercept service providers), my personal health information such as: (1) my name, birth date, address, or telephone number; (2) medical records and treatment information; (3) information about my health benefits or health insurance coverage; and (4) financial information about me.

I understand that, once my protected health information has been disclosed to Intercept, federal privacy laws may no longer protect the information from further disclosure, but Intercept has agreed to use and disclose my information only for purposes of providing Program services or as indicated in this Authorization.

Intercept may use my personal health information for the following purposes:

- Contact me by phone, mail, or email to provide information about the Program;
- Verify the accuracy of the information on this form and request additional financial and insurance information;
- Determine my eligibility for the Program and the specific services of the Program, such as financial assistance;
- Facilitate the provision of Program services to me, including by delivering Program services requested by me or my physician, including compliance and persistency messaging;
- Send, via email, postal mail or fax, prescription information to my pharmacy;
- For Intercept's medial research and related purposes, including to help develop new products, services, and programs; and/or
- As necessary to comply with applicable laws, including, without limitations, any safety reporting obligations.

I also understand that:

- I do not have to sign this Authorization. My treatment, payment for treatment, insurance enrollment, or eligibility for insurance benefits will not be affected. If I do not sign this Authorization, however, I will not be eligible to receive Program services.
- This Authorization will remain in effect until I am no longer participating in the Program, at which time it will expire.
- I may revoke (cancel) this Authorization at any time by mailing a letter requesting such cancellation to Interconnect at P.O. Box 580, Somerville, NJ, 08876 or by emailing Interconnect at privacyprotection@interceptpharma.com. If I revoke this Authorization, my Healthcare Providers and Insurers are not permitted to make further disclosures of my personal health information to Intercept, except for disclosures made in reliance on this Authorization. Revocation of this Authorization will not affect Intercept's ability to use or disclose information it has received. If I revoke this Authorization, I will no longer be able to receive Program services.
- I am entitled to a copy of this signed Authorization.
- Intercept may change or discontinue the Program at any time. Significant changes to the Program will be communicated in a timely manner to all participants of the Program.
- The information disclosed pursuant to this Authorization may be subject to redisclosure by the recipient and may no longer be protected by HIPAA once disclosed.
- I will contact the Program if my financial status or insurance coverage changes.

Additional opt-in: By checking this box, I authorize Intercept and third-party companies working on Intercept's behalf, to contact me by mail, email, telephone, or text message for (i) marketing purposes, including to provide me with information about Intercept's products, services, and programs or other topics of interest, and/or (ii) to conduct market research.

Patient/personal representative signature

Date

Patient/personal representative printed name

Relationship (personal representative), if applicable (parent, power of attorney, etc)

Please sign and fax the completed form and required documentation to:

1-855-686-8730

The form may also be sent by **Mail:** Interconnect, P.O. Box 580, Somerville, NJ 08876

Email: info@interconnectsupport.com

Patient Assistance Application

You are eligible for this program if:

- You do not have any prescription drug coverage for OCALIVA® (obeticholic acid)
- You are an adult (18 years and older) diagnosed with primary biliary cholangitis
- You are a US citizen or permanent resident of the United States
- Your annual gross household income is at or below 400% of the Federal Poverty Level for all family sizes. Please visit the US Department of Health & Human Services, Office of the Assistant Secretary for Planning and Evaluation, to view the current Federal Poverty Guidelines at <https://aspe.hhs.gov/poverty-guidelines>

Patient information (to be completed by the patient)

_____	_____	____/____/____	Male	Female	
First name	Last name	Date of birth			
_____		_____			
Address		City			
_____	_____	_____	_____	_____	
State	ZIP	Preferred contact:	Email	Home phone	Cell phone
_____		_____	_____		
Email address		Home phone	Cell phone		
Are you a US citizen?	YES	NO	If no, are you a permanent resident of the United States?	YES	NO
Total household income \$	_____	No. of people in your household	_____		
Do you have private prescription insurance coverage?	YES	NO			
Have you enrolled in Medicaid?	YES	NO			
Are you enrolled in Medicare Part A and/or Part B?	YES	NO	Medicare ID no. (if applicable):	_____	
Ship OCALIVA to:	Patient's home	HCP's office			

Patient declaration

I know that to qualify for free medicine my household gross income must be at or below 400% of the Federal Poverty Level, and I certify that the patient financial information I have provided is correct. I certify I have no health plan coverage for OCALIVA; this includes Medicare, Medicaid, or other public programs. I do not have the resources to pay for OCALIVA. I agree to provide Interconnect® proof of my income, if requested. I agree that if my certification about my income is false, I will reimburse Intercept Pharmaceuticals, Inc.



Patient's signature

Date

Statement of Medical Necessity

To the best of my knowledge, this patient has no coverage (including Medicare, Medicaid, or other Federal healthcare programs) for OCALIVA. I certify that, in my medical judgment, OCALIVA is medically necessary for this patient, and that I will be supervising this patient's treatment.



Prescriber's signature

Date

Please sign and fax the completed form
and required documentation to:

1-855-686-8730

The form may also be sent by

Mail: Interconnect, P.O. Box 580, Somerville, NJ 08876

Email: info@interconnectsupport.com

Additional documentation attached

Please see Important Safety Information for OCALIVA on page 7 and [Medication Guide](#) and full [Prescribing Information](#), including Boxed Warning for OCALIVA 5 mg and 10 mg tablets or visit ocalivahcp.com.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is OCALIVA® (obeticholic acid)?

OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have not responded well enough to UDCA, or alone for adults who cannot tolerate UDCA. It is not known if taking OCALIVA will improve your chance of survival or improve your symptoms of PBC. There are ongoing studies to find out how OCALIVA works over a longer period of time.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about OCALIVA?

OCALIVA may cause serious side effects including:

Worsening of liver problems, liver failure, in some cases leading to death, have happened in people with PBC with advanced liver cirrhosis when OCALIVA was taken more often than recommended.

If you have primary biliary cholangitis (PBC) with advanced cirrhosis, you may need a lower dose of OCALIVA. Before you start OCALIVA, and during your treatment with OCALIVA, your healthcare provider will do tests to check your liver. These tests will help your healthcare provider decide how much OCALIVA you should take and how often you should take it. If you have worsening liver problems, your dose of OCALIVA may be changed, stopped for a period of time, or stopped completely by your healthcare provider.

Tell your healthcare provider right away if you have any of the following symptoms of worsening liver problems during treatment with OCALIVA

- Swelling of your stomach area from a build-up of fluid; yellowing of your skin or the whites of your eyes; black, tarry, or bloody stools; coughing up or vomiting blood, or your vomit looks like "coffee grounds"; or mental changes (such as confusion, sleepier than usual or harder to wake up, slurred speech, mood swings, or changes in personality)

Tell your healthcare provider right away if you have any of the following symptoms during treatment with OCALIVA and they are severe or do not go away:

- Stomach-area pain, nausea, vomiting, or diarrhea; loss of appetite or weight loss; new or worsening fatigue, weakness, fever, or chills; light-headedness; less frequent urination

Who should not take OCALIVA?

Do not take OCALIVA if you have or had a complete blockage in the bile ducts in your liver or gallbladder.

What are the possible side effects of OCALIVA?

OCALIVA may cause serious side effects including:

- See "What is the most important information I should know about OCALIVA?"
- **Severe Itching.** Itching (pruritus) is a common side effect and can sometimes become severe (intense itching or itching all over your body). Severe itching can cause discomfort, problems sleeping, and problems doing daily activities, and usually needs to be treated. Tell your healthcare provider if you get severe itching or if your itching gets worse.
- **Decreases in Good Cholesterol.** Decreases in HDL-C ("good cholesterol") have been observed in patients taking OCALIVA. Your healthcare provider will check your cholesterol levels during treatment to see if you should continue taking OCALIVA.

The most common side effects of OCALIVA include: pruritus (itching of the skin), tiredness, stomach pain and discomfort, rash, joint pain, mouth and throat pain, dizziness, constipation, swelling in your hands, ankles or feet, fast or irregular heartbeat, fever, changes in how your thyroid gland works, and eczema (skin dryness, irritation, redness, crusting, or drainage).

These are not all the possible side effects associated with OCALIVA. Call your healthcare provider for medical advice about side effects.

What should I tell my healthcare provider before taking OCALIVA?

Before taking OCALIVA, tell your healthcare provider about all of your medical conditions, including if you:

- **are pregnant or plan to become pregnant.** It is not known if OCALIVA will harm your unborn baby.
- **are breastfeeding or plan to breastfeed.** It is not known if OCALIVA passes into your breastmilk. Talk with your healthcare provider about the best way to feed your baby if you take OCALIVA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. OCALIVA can affect the way certain medicines work. Certain other medicines may affect the way OCALIVA works.

Please see [Medication Guide](#) and full [Prescribing Information](#) for OCALIVA 5 mg and 10 mg tablets or visit ocaliva.com.

Available by prescription only.

To report negative side effects of OCALIVA, please contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or you may report to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.